Patent Term Extension Application for UNLOXCYT® (cosibelimab-ipdl), Patent No. 11,834,505 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0502

Patent Term Extension Application for UNLOXCYT® (cosibelimab-ipdl), Patent No. 11,834,505

Documents

Comments

Description

Open

Comment Period OpensFeb 28, 2025

Comment Period ClosesJun 16, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT FR Doc: 2026-07422	Apr 16, 2026	--

CDER

Patent Term Extension Application

Patent No. 11,834,505

UNLOXCYT® (cosibelimab-ipdl)

Checkpoint Therapeutics, Inc.

Foley & Lardner LLP

Open